TVEC and Preop Radiation for Sarcoma (8 ml Dose)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04599062|
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : October 22, 2020
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy.
Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.
|Condition or disease||Intervention/treatment||Phase|
|Soft Tissue Sarcoma||Drug: Talimogene Laherparepvec Radiation: Radiotherapy||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas|
|Actual Study Start Date :||September 10, 2020|
|Estimated Primary Completion Date :||April 30, 2021|
|Estimated Study Completion Date :||June 30, 2024|
Talimogene Laherparepvec in combination with radiotherapy
Talimogene Laherparepvec Dose Levels:
Dose 0 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed weekly
Dose -1 = talimogene laherparepvec up to 8.0 mL of 108 PFU/mL dosed every 2 weeks
Drug: Talimogene Laherparepvec
Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
- Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: 14 weeks ]A DLT is defined as any of the following talimogene laherparepvec-related toxicity or related to the combination of talimogene laherparepvec and radiation therapy during treatment and up to 4 weeks after the last talimogene laherparepvec injection: Grade 3 or greater immune-mediated adverse events, Grade 3 or greater allergic reactions, any grade plasmacytoma, any other unexpected grade 3 or greater hematologic or non-hematologic toxicity, with the exceptions of: any grade of alopecia, expected radiation related skin toxicity of any grade, Grade 3 arthralgia or myalgia, brief (< 1 week) grade 3 fatigue, Grade 3 fever, Grade 3 diarrhea or vomiting responding to supportive case.
- Phase 2: Number of Subjects With Pathologic Tumor Necrosis ≥ 90% Following Concurrent Radiation Therapy and Talimogene Laherparepvec. [ Time Frame: 14 weeks ]At the end of the neoadjuvant therapy, patients will undergo resection of the treated tumor. The percentage of post treatment tumor necrosis must be documented. The primary end point for this study is pathologic complete response (pCR), and is defined as ≥ 90% tumor necrosis following concurrent radiation therapy and talimogene laherparepvec.
- Overall Response Rate (ORR) as Measured by RECIST [ Time Frame: 24 months ]Overall response rate (ORR) as measured by RECIST 1.1. Complete response is the disappearance of all target lesions.Partial response is a 30% decrease in the sum of the longest dimensions of the target lesions, relative to baseline. Progressive disease is an increase of 20% or more in the sum of the longest dimension of target lesions. Stable disease is a decrease in the tumor size of < 30% or an increase of < 20%..
- Time to Disease Progression (TTP) [ Time Frame: 24 months ]TTP is defined as the time from enrollment until objective tumor progression
- Overall Survival Rate (OS) at 5 Years [ Time Frame: 5 years ]Subjects will be followed for overall survival rate (OS) at 5 years from the last enrollment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04599062
|Contact: Varun Monga, MDfirstname.lastname@example.org|
|United States, Iowa|
|University of Iowa Hospitals and Clinics||Recruiting|
|Iowa City, Iowa, United States, 52242|
|Contact: Varun Monga, MD 319-384-9497 email@example.com|
|Principal Investigator: Varun Monga, MD|
|Principal Investigator:||Varun Monga, MD||University of Iowa Holden Comprehensive Cancer Center|